<!DOCTYPE html>
<html class="no-js" lang="">

<head>
  <!-- Google Tag Manager -->
  <script>
    (function(w, d, s, l, i) {
      w[l] = w[l] || [];
      w[l].push({
        'gtm.start': new Date().getTime(),
        event: 'gtm.js'
      });
      var f = d.getElementsByTagName(s)[0],
        j = d.createElement(s),
        dl = l != 'dataLayer' ? '&l=' + l : '';
      j.async = true;
      j.src =
        'https://www.googletagmanager.com/gtm.js?id=' + i + dl;
      f.parentNode.insertBefore(j, f);
    })(window, document, 'script', 'dataLayer', 'GTM-5WX4RRR');
  </script>
  <!-- End Google Tag Manager -->

    <meta charset="UTF-8">
  <title>Efficacy | NOURIANZ™ (istradefylline)</title>
  <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="google-site-verification" content="F3DullM3mnZSi9p84pQJz2XO2pqXFG8ao0qtvAehfkQ" />

  <!-- SEO -->
  <link rel="canonical" href="">
  <meta name="description" content="See the trial data and Important Safety Information for NOURIANZ. Also, view the Prescribing Information.">
  <meta name="keywords" content="">
  <meta property="og:type" content="website">
  <meta property="og:url" content="www.nourianzhcp.com/efficacy">
  <meta property="og:site_name" content="www.nourianzhcp.com">
  <meta property="og:title" content="Efficacy | NOURIANZ™ (istradefylline)">
  <meta property="og:description" content="Learn about the trial outcomes and safety information for this FDA-approved therapy.">
  <meta property="og:image" content="">
  <meta property="og:locale" content="en_US">
  <meta property="og:type" content="website">
  <meta name="twitter:card" content="summary_large_image">
  <meta name="twitter:title" content="Efficacy | NOURIANZ™ (istradefylline)">
  <meta name="twitter:description" content="Learn about the trial outcomes and safety information for this FDA-approved therapy.">
  <meta name="twitter:image" content="">
  <meta name="twitter:card" content="summary">
  <!-- SEO -->

  <link rel=icon href="/assets/images/global/favicon.png">

  <!-- link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@mdi/font@5.8.55/css/materialdesignicons.min.css" -->
 
  <link rel="stylesheet" href="/assets/css/reset.css" />
  <link rel="stylesheet" href="/assets/css/bootstrap.min.css" />
  <link rel="stylesheet" href="/assets/css/bootstrap-grid.min.css" />
  <link rel="stylesheet" href="/assets/css/base.css" />

  
  <!-- Azure Media Player -->
  <link rel="stylesheet" type="text/css" href="//amp.azure.net/libs/amp/2.3.5/skins/amp-default/azuremediaplayer.min.css">
  <script src="//amp.azure.net/libs/amp/2.3.5/azuremediaplayer.min.js"></script>
  <link rel="stylesheet" href="/assets/css/amp.css" />

</head>

<body class="page internal-page efficacy">

  <!-- Google Tag Manager (noscript) -->
  <noscript>
    <iframe src="https://www.googletagmanager.com/ns.html?id=GTM-5WX4RRR" height="0" width="0" style="display:none;visibility:hidden"></iframe>
  </noscript>
  <!-- End Google Tag Manager (noscript) -->

  <header>
    <div class="headertop bg-light w-100">
      <div class="container">
        <div class="row">
          <div class="col-12 col-md-5">
            <span class="text-light-gray text-left">This site is for US healthcare professionals only</span> 
          </div>
          <div class="col-12 col-md-7">
              <ul class="links d-flex mt-2 mt-md-0 mr-md-4 justify-content-around justify-content-md-end">
                <li class="pl-0"><a href="https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf" class="fs-bolder text-light-gray" target="_blank">Full Prescribing Information</a></li>
                <li></li>
                <li><a href="#isi" id="goToIsi" class="fs-bolder text-light-gray">Important Safety Information</a></li>
                <li></li>
                <li class="pr-0"><a href="https://www.nourianz.com/" target="_blank" class="fs-bolder text-light-gray">Patient Website</a></li>
              </ul>
          </div>
        </div>
      </div>
    </div>

    <div class="headermenu">
      <div class="container">
        <div class="row">
          <div class="col-6"> <div class="d-flex align-items-center"><a href="/" class="logo d-block pt-4"> <img src="/assets/images/global/logo-nourianz.png" width="174" height="46" alt="Nourianz logo" class="img-responsive"> </a></div> </div>
          <div class="col-6 d-flex justify-content-end pr-sm-1 pr-lg-4">
              <div class="d-none d-md-block extra-ctas">
                <a href="/stay-informed" class="gu fs-ex-bold text-gray d-block mt-4 ">GET UPDATES</a>
              </div>
              <div class="burger bg-blue pt-4">
                <div class="d-flex align-items-center flex-column mb-2">
                  <div class="bar1"></div>
                  <div class="bar2"></div>
                  <div class="bar3"></div>
                </div>
                <p class="fs-medium  w-100 text-center text-white">Menu</p>
              </div>
          </div>
        </div>
      </div>

      <div class="menubar bg-blue">
          <div class="container">
            <div class="row">
              <div class="col-12 col-md-4">
                <div class="my-3">
                  <div class="d-md-none extra-ctas text-center">
                    <a href="/stay-informed" class="gu d-block mx-4 mt-4">GET UPDATES</a>
                  </div>
                </div>
                <ul class="menu">
                  <li><a href="/about-parkinsons-disease/" class="m-about">Role of Adenosine in PD</a></li>
                  <li class="submenu">
                    <a href="/mechanism-of-action/" class="m-moa">The NOURIANZ Difference</a>
                    <ul>
                      <li><a href="/mechanism-of-action/">Mechanism of Action</a></li>
                      <li><a href="/mechanism-of-action/#pet-scans">PET Scans</a></li>
                    </ul>
                  </li>
                  <li class="submenu">
                    <a href="/efficacy/" class="m-efficacy">Efficacy</a>
                    <ul>
                      <li><a href="/efficacy/#off-time">Primary Endpoint - "Off" Time</a></li>
                      <li><a href="/efficacy/#on-time">Secondary Endpoint - "On" Time</a></li>
                    </ul>
                  </li>
                </ul>
              </div>

              <div class="col-12 col-md-4">
                <ul class="menu">
                  <li class="submenu">
                    <a href="/safety/" class="m-safety">Safety</a>
                    <ul>
                      <li><a href="/safety/#trial-design">Trial Design</a></li>  
                      <li><a href="/safety/#adverse-reactions">Adverse Reactions</a></li>
                    </ul>
                  </li>
                  <li class="submenu">
                    <a href="/dosing/" class="m-dosing">Dosing</a>
                    <ul>
                      <li><a href="/dosing/#once-daily">One Pill, Once-Daily Dosing</a></li>
                      <li><a href="/dosing/#dosage-adjustments">Dosage Adjustments</a></li>
                    </ul>
                  </li>
                </ul>
              </div>

              <div class="col-12 col-md-4">
                <ul class="menu">
                  <li class="submenu">
                    <a href="/access/" class="m-access">Patient Support</a>
                    <ul>
                      <li><a href="/access/">Co-pay Assistance</a></li>
                      <li><a href="/access/#starting">Starting Patients on NOURIANZ</a></li>
                    </ul>
                  </li>
                  <li class="submenu">
                    <a href="/resources/" class="m-resources">NOURIANZ Resources</a>
                    <ul>
                      <li><a href="/resources/#educational">Educational Presentations</a></li>
                      <li><a href="/resources/#downloadable">Downloadable Materials</a></li>
                    </ul>
                  </li>
                </ul>
              </div>

            </div>
          </div>      
      </div>
    </div>

  </header>
  <div id="content-wrap" class="content-wrap"><section>
  <div class="container" id="off-time">
    <div class="row">
      <div class="col-12">
        <div class="page-label">
          <h1 class="fs-medium">Primary Endpoint - “Off” Time</h1>
        </div>
        <p class="mb-0"><strong class="fs-medium text-secondary light-60">Primary Endpoint</strong></p>
        <h2 class="text-secondary mt-2">NOURIANZ<sup class="sup3">&reg;</sup> is the first and only adjunct therapy that reduces “off” time <br class="d-none d-lg-block">by lifting the brake of adenosine<sup class="sup3">1,2</sup></h2>
      </div>
    </div>

    <div class="row">
      <div class="col-12 col-lg-8">

        <p><strong>Study description:</strong> Randomized, 12-week, multicenter, double-blind, placebo-controlled studies of NOURIANZ 20 mg and 40 mg as adjunctive treatment to levodopa treatment in patients with PD (mean age=65 years) experiencing “off” time (mean approximately 6 hours/day).</p>
        <p>In Studies 1 & 2, patients were randomized to once-daily treatment with NOURIANZ 20 mg, 40 mg, or placebo with the primary endpoint of change from baseline in % of awake time spent in the “off” state</p>
        <ul class="square-bullets">
          <li>Study 1 (N=195) was conducted in the U.S. and Canada</li>
          <li>Study 2 (N=225) was conducted in the U.S.</li>
        </ul>
        <p>In Studies 3 & 4, patients were randomized equally to treatment with NOURIANZ 20 mg, 40 mg, or placebo with the primary endpoint of change from baseline spent in “off” time/day</p>
        <ul class="square-bullets">
          <li>Study 3 (N=357) was conducted in Japan</li>
          <li>Study 4 (N=366) was conducted in Japan</li>
        </ul>
        <p>Secondary endpoint in all 4 studies was change from baseline in “on” time without troublesome dyskinesia. Endpoints measured using 24-hour patient diaries.<sup>1,2</sup>  </p>
        <p>All enrolled patients were on stable doses of baseline therapy for the duration of the studies. Baseline therapy was levodopa/carbidopa (Studies 1, 2, 3, and 4) or levodopa/benserazide (Studies 3 and 4) for all patients with or without other concomitant baseline medications for PD, including dopamine agonists (85%), COMT inhibitors (38%), MOA-B inhibitors (40%), anticholinergics (13%), and/or amantadine (33%).<sup>1,2</sup></p>
        <p class="footnote">
          <small>COMT, catechol-o-methyl transferase; MAO, monoamine oxidase.</small></p>
      </div>
      <div class="col-12 col-lg-10 mt-5">
        <h3 class="fs-bold">Based on 24-hour patient diaries in Studies 3 & 4: NOURIANZ reduced “off” time<sup> 1,3</sup></h3>
        
      </div>

    </div>
    <div class="row">
      <div class="col-12 col-lg-6 mb-3">
          <div class="graphic-1-efficacy mx-auto ml-lg-0 my-5">
            <img class="d-lg-none" src="/assets/images/efficacy/chart-1-mobile.png" alt="Nourianz Efficacy chart 1" />
            <img class="w-100 d-none d-lg-block ml-0" src="/assets/images/efficacy/chart-1.png" alt="Nourianz Efficacy chart 1" />
          </div>
          <p class="footnote">
            <small class="ident-sup"><sup class="ident">a</sup>Least squares (LS) mean change from baseline (ANCOVA).<br class="d-none d-lg-block"/> ANCOVA, analysis of covariance.</small>
          </p>
      </div>
      <div class="col-12 col-lg-5 pt-lg-5">
        <ul class="pt-lg-5 square-bullets">
          <li>At Week 12, patients taking NOURIANZ in clinical trials saw a significant decrease in “off” time from baseline compared to placebo in all 4 studies (N=1,143 PD patients)<sup>1</sup></li>
        </ul>
      </div>
    </div>
   
  </div>
</section>

<section class="bg-light">
  <div class="container">
    <div class="row">
      <div class="col-12">
        <h3 class="fs-bold">Studies 1 and 2: Change in “off” time from baseline to endpoint (12 weeks),<br class="d-none d-lg-block"> daily awake “off” time (% of awake hours)<sup>1,3</sup></h3>
        
        <div class="graphic-2-efficacy w-100 mb-4">
          <img class="w-100 d-lg-none" src="/assets/images/efficacy/chart-2-mobile.png" alt="Change from baseline to endpoint chart" />
          <img class="w-100 ml-lg-0 d-none d-lg-block" src="/assets/images/efficacy/chart-2.png" alt="Change from baseline to endpoint chart" />
        </div>
      </div>
    </div>

    <div class="row">
      <div class="col-12 col-lg-6">
        <ul class="square-bullets">
          <li>Pre-specified analysis for Study 1 was ANOVA, and for Study 2 was ANCOVA*</li>
        </ul>
      </div>

      <div class="col-12 col-lg-6">
        <p>
          <small class="ident-sup"><span class="ident2">*</span>Least squares mean change from baseline (ANOVA in Study 1, ANCOVA in Study 2).<br class=""/>ANOVA, analysis of variance; ANCOVA, analysis of covariance.</small>
        </p>
      </div>
    </div>
    
  </div>
</section>


<section>
  <div class="container" id="on-time">
    <div class="row">
      <div class="col-12 col-lg-9">
        <div class="page-label">
          <h3 class="fs-medium">Secondary Endpoint - “On” Time</h3>
        </div>
        <div class="page-label mb-0"><h3 class="fs-medium text-secondary light-60 mb-0">Secondary Endpoint</h3></div>
        <h2 class="text-secondary mt-2">NOURIANZ lifts the brake of adenosine to help increase good “on” time<sup class="sup3">1,2</sup></h2>
        <h3 class="fs-bold">Based on 24-hour patient diaries: NOURIANZ reduced “off” time and was shown to increase good “on” time without troublesome dyskinesia at Week 12<sup>1,3</sup></h3>
      </div>
    </div>

    <div class="row">
      <div class="col-12 col-lg-6">
        <div class="graphic-2-efficacy mx-auto my-5">
          <img class="w-100 d-md-none" src="/assets/images/efficacy/chart-3-mobile.png" alt="Nourianz Efficacy chart 1" />
          <img class="w-100 d-none d-md-block" src="/assets/images/efficacy/chart-3.png" alt="Nourianz Efficacy chart 1" />
        </div>
        <p>Good “on” time=“on” time without troublesome dyskinesia plus “on” time with <span class="text-nowrap">non-troublesome</span> dyskinesia.</p>
        <p class="footnote">
          <small class="ident-sup fontSize12"><sup class="ident sup2">a</sup>Least squares mean change from baseline (ANOVA in Study 1, ANCOVA in Studies 2, 3, and 4).
          <br />ANOVA, analysis of variance; ANCOVA, analysis of covariance.
          <br />Baseline therapy was levodopa/carbidopa and/or levodopa/benserazide for all patients with or without <br class="d-none d-md-block"> other concomitant medications for PD.</small>
        </p>
      </div>
      <div class="col-12 col-lg-5 mt-lg-5 ml-lg-5">
        <ul class="square-bullets">
          <li class="mb-0">At Week 12, patients treated with NOURIANZ experienced an increase in good “on” time.<sup>1,3</sup></li>
          <div>
            <ul>
              <li class="circles-outline">A change from baseline in good “on” time without troublesome dyskinesia  (i.e., “on” time without dyskinesia plus “on” time with non-troublesome dyskinesia) was a secondary efficacy endpoint</li>
            </ul>
          </div>
          <li>Increases from baseline with NOURIANZ 20 mg ranged from 0.90 to 1.35 hours. Nominal &nbsp<em>P</em>&nbsp values: <em>P</em>=0.135 in Study 2; <em>P</em>=0.085 in Study 3; <em>P</em>=0.008 in Study 4</li>
          <li>Increases from baseline with NOURIANZ 40 mg ranged from 0.85 to 1.45 hours. Nominal &nbsp<em>P</em>&nbsp values: <em>P</em>=0.026 in Study 1; <em>P</em>=0.048 in Study 3; <em>P</em>=0.008 in Study 4</li>
          <li>Increases from baseline with placebo ranged from 0.28 to 0.80 hours</li>
        </ul>
        <p>NOURIANZ in combination with levodopa may cause dyskinesia or exacerbate pre-existing dyskinesia.</p>
        
      </div>
    </div>
   
  </div>
</section>

<section class="bg-light">
  <div class="container">
    <div class="row">
      <div class="col-12">
        <h3 class="fs-bold">NOURIANZ was evaluated in patients taking levodopa treatment with or without <br class="d-none d-lg-block">other concomitant baseline medications for PD<sup>1,3</sup></h3>
      </div>
    </div>
    <div class="row pt-3">
      <div class="col-12 col-lg-8">
        <div class="chart-efficacy-2">
          <img class="w-100" src="/assets/images/efficacy/chart-4.png" alt="Nourianz evaluated on patients" />
        </div>
      </div>
    </div>
   
  </div>
</section>

<section class="bg inner bg-efficacy">
  <div class="bg-full w-100"></div>
  <div class="container d-flex align-tems-end">
      <div class="row banner__content">
        <div class="col-12 col-6">
          <p>
            When patients experience <br>
            “off” time on levodopa<br>
            carbidopa, consider<br>
            adding NOURIANZ.<sup class="fontFamily-FSIndustrieCd">1</sup>
          </p>
          <div class="mt-5 d-flex justify-content-start">
            <a class="btn btn-primary inner text-center" href="/safety/">See safety info</a>
          </div>
        </div>
      </div> 

      <div class="actor-portrayals"><p>Actor Portrayals.</p></div>
  </div>
</section>

<section class="pt-0"></section></div>

<div class="isi isiPersistent bottomFixedIsi" id="bottomFixedIsi">
		<div class="container">
		<a href="#" class="isi-arr topBtmArrow">&nbsp;</a>

		<div class="row">
			<div class="col-12 col-lg-3 pl-lg-5">
					<p class="fs-bold text-secondary pb-1">Indication</p>
					<p class='indication-text'>NOURIANZ<sup>&reg;</sup> (istradefylline) is an adenosine receptor antagonist indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing “off” episodes. </p>
			</div>
			<div id="isi" class="col-12 col-lg-9 pr-lg-5 pt-2 pt-lg-0">
					<p class="fs-bold text-secondary pb-1">Important Safety Information</p>
					<p><strong>Warnings and Precautions</strong></p>
					<p><strong>Dyskinesia:</strong> NOURIANZ in combination with levodopa may cause dyskinesia or exacerbate pre-existing dyskinesia. In clinical trials, 1% of patients treated with either NOURIANZ 20&nbsp;mg or 40&nbsp;mg discontinued treatment because of dyskinesia, compared to 0% for placebo.</p>
					<p><strong>Hallucinations / Psychotic Behavior:</strong> Because of the potential risk of exacerbating psychosis, patients with a major psychotic disorder should not be treated with NOURIANZ. Consider dosage reduction or discontinuation if a patient develops hallucinations or psychotic behaviors while taking NOURIANZ.</p>
					<p><strong>Impulse Control / Compulsive Behaviors:</strong> Patients treated with NOURIANZ and one or more medication(s) for the treatment of Parkinson’s disease (including levodopa) may experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge or compulsive eating, and/or other intense urges, and the inability to control these urges. In clinical trials, 1 patient treated with NOURIANZ 40&nbsp;mg was reported to have impulse control disorder, compared to no patient on NOURIANZ 20&nbsp;mg or placebo.</p>
					<p><strong>Drug Interactions</strong></p>
					<p>The maximum recommended dosage in patients taking strong CYP3A4 inhibitors is 20&nbsp;mg once daily. Avoid use of NOURIANZ with strong CYP3A4 inducers.</p>
					<p><strong>Specific Populations</strong></p>
					<p><strong>Pregnancy:</strong> Based on animal data, may cause fetal harm. </p>
					<p><strong>Hepatic impairment:</strong> The maximum recommended dosage of NOURIANZ in patients with moderate hepatic impairment is 20&nbsp;mg once daily. Avoid use in patients with severe hepatic impairment.</p>
					<p><strong>Adverse Reactions</strong></p>
					<p>The most common adverse reactions with an incidence ≥5% and occurring more frequently than with placebo were dyskinesia (15%, 17%, and 8%), dizziness (3%, 6%, and 4%), constipation (5%, 6%, and 3%), nausea (4%, 6%, and 5%), hallucination (2%, 6%, and 3%), and insomnia (1%, 6%, and 4%) for NOURIANZ 20&nbsp;mg, 40&nbsp;mg, and placebo, respectively.</p>
					<p>You are encouraged to report suspected adverse reactions to Kyowa Kirin, Inc. at <span class="no-wrap">1-844-768-3544</span> or FDA at <br class="d-none d-lg-block" /><span class="no-wrap">1-800-FDA-1088</span> or <a href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program" class="f-normal">www.fda.gov/medwatch</a>.</p>
					<p><strong>Please see full <a href="/assets/pdf/nourianz-full-prescribing-information.pdf" target="_blank">Prescribing Information</a> for NOURIANZ.</strong></p>
			</div>

			<div class="col-12 px-lg-5 pt-2 pb-4 py-lg-4">
					<div class="f-ref homeref">
						<p>
							<strong>References: 1.</strong> NOURIANZ. Prescribing Information. Kyowa Kirin, Inc; 2020. Accessed April 1, 2021. <a href="https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf" target="_blank">https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf</a>.
							<strong> 2.</strong>  Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson’s disease: review of recent trials. <i><em>Mov Disord</em>.</i> 2013;28(2):131-144.
						</p>

					</div>
					<div class="f-ref aboutref">
						<p>
							<strong>References: 1.</strong> Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials. <em>Mov Disord</em>. 2013;28(2):131-144. 
							<strong>2.</strong> Mori A. Mode of action of adenosine A<sub>2A</sub> receptor antagonists as symptomatic treatment for Parkinson’s disease. <em>Int Rev Neurobiol</em>. 2014;119:87-116. 
							<strong>3.</strong> Varani K, Vincenzi F, Tosi A, et al. A<sub>2A</sub> adenosine receptor overexpression and functionality, as well as TNF-α levels, correlate with motor symptoms in Parkinson’s disease. <em>FASEB J</em>. 2010;24(2):587-598. doi:10.1096/fj.09-141044.  
							<strong>4.</strong> Fuxe K, Marcellino D, Genedani S, Agnati L. Adenosine A<sub>2A</sub> receptors, dopamine D<sub>2</sub> receptors and their interactions in Parkinson's disease. <em>Mov Disord</em>. 2007;22(14):1990-2017. doi: 10.1002/mds.21440. 
							<strong>5.</strong> Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA. Role of adenosine A<sub>2A</sub> receptors in parkinsonian motor impairment and L-DOPA-induced motor complications. <em>Prog Neurobiol</em>. 2007;83(5):293-309. 
							<strong>6.</strong> Morelli M, Blandini F, Simola N, Hauser RA. A<sub>2A</sub> receptor antagonism and dyskinesia in Parkinson's disease. <em>Parkinsons Dis.</em> 2012;2012:489853. doi: 10.1155/2012/489853. 
							<strong>7.</strong> Mishina M, Ishiwata K. Adenosine receptor PET imaging in human brain. <em>Int Rev Neurobiol</em>. 2014;119:51-69. doi:10.1016/B978-0-12-801022-8.00002-7.
							<strong>8.</strong> The voice of the patient: Parkinson’s disease. Silver Spring, MD: US Food and Drug Administration; April 2016. https://www.fda.gov/media/124392/download. Accessed June 11, 2019. 
							<strong>9.</strong> Hickey P, Stacy M. Available and emerging treatments for Parkinson’s disease: a review. <em>Drug Des Devel Ther</em>. 2011;5:241-254.  
							<strong>10.</strong> Stocchi F, Antonini A, Barone P, et al. Early DEtection of wEaring off in Parkinson disease: the DEEP study. <em>Parkinsonism Relat Disord</em>. 2014;20(2):204-211.
						</p>
					</div>
					
					<div class="f-ref moaref">
						<p>
							<strong>References: 1.</strong> NOURIANZ. Prescribing Information. Kyowa Kirin, Inc; 2020. Accessed April 1, 2021. <a href="https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf">https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf</a>
							&nbsp<strong> 2.</strong> Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson’s disease: review of recent trials. <em>Mov Disord</em>. 2013;28(2):131-144. 
							<strong>3.</strong> Jenner P. Istradefylline, a novel adenosine A<sub>2A</sub> receptor antagonist, for the treatment of Parkinson’s disease. <em>Expert Opin Investig Drugs</em>. 2005;14(6):729-738. 
							<strong>4.</strong> Brichta L, Greengard P, Flajolet M. Advances in the pharmacological treatment of Parkinson’s disease: targeting neurotransmitter systems. <em>Trends Neurosci</em>. 2013;36(9):543-554.  
							<strong>5.</strong> Kaakkola S, Wurtman RJ. Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study. <em>Brain Res</em>. 1992;587(2):241-249.  
							<strong>6.</strong> Kong P, Zhang B, Lei P, et al. Neuroprotection of MAO-B inhibitor and dopamine agonist in Parkinson disease. <em>Int J Clin Exp Med</em>. 2015;8(1):431-439.  
							<strong>7.</strong> Ossola B, Schendzielorz N, Chen SH, et al. Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia. <em>Neuropharmacology</em>. 2011;61(4):574-582. 
							<strong>8.</strong> Rubí B, Maechler P. Minireview: new roles for peripheral dopamine on metabolic control and tumor growth: let’s seek the balance. <em>Endocrinology</em>. 2010;151(12):5570-5581. doi:10.1210/en.2010-0745. 
							<strong>9.</strong> Gerlach M, Double K, Arzberger T, Leblhuber F, Tatschner T, Riederer P. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum.  <em>J Neural Transm (Vienna)</em>. 2003;110(10):1119-1127.  
							<strong>10.</strong> Ishibashi K, Miura Y, Wagatsuma K, Toyohara J, Ishiwata K, Ishii K. Adenosine A<sub>2A</sub> receptor occupancy by long-term istradefylline administration in Parkinson’s disease. <em>Mov Disord</em>. 2021;36(1):268-269. doi:10.1002/mds.28378.
						</p>
					</div>

					<div class="f-ref effref">
						<p>
							<strong>References: 1.</strong> NOURIANZ. Prescribing Information. Kyowa Kirin, Inc; 2020. Accessed April 1, 2021. <a href="https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf" target="_blank" class="paragraphColor">https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf</a>
							&nbsp<strong> 2.</strong> Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson’s disease: review of recent trials. <em>Mov Disord</em>. 2013;28(2):131-144. 
							<strong>3.</strong> Data on file. Kyowa Kirin Pharmaceutical Development, Inc., Princeton, NJ.
						</p>
					</div>
					<div class="f-ref safetyref">
						<p>
							<strong>References: 1.</strong> NOURIANZ. Prescribing Information. Kyowa Kirin, Inc; 2020. Accessed April 1, 2021. <a href="https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf" target="_blank">https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf</a>
							&nbsp<strong>2.</strong> Data on file. Kyowa Kirin Pharmaceutical Development, Inc., Princeton, NJ.
						</p>
					</div>
					<div class="f-ref dosingref">
						<p><strong>Reference: 1.</strong> NOURIANZ. Prescribing Information. Kyowa Kirin, Inc; 2020. Accessed April 1, 2021. <a href="https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf" target="_blank">https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf</a>
					</div>
					<div class="f-ref accessref">
						<p><strong>Reference: 1.</strong> NOURIANZ. Prescribing Information. Kyowa Kirin, Inc; 2020. Accessed April 1, 2021. <a href="https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf" target="_blank">https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf</a>
					</div>
				
			</div>

		</div>

</div></div>

<footer>

	<div class="isi footerIsi" id="footerIsi">	
		<div class="container">
		<a href="#" class="isi-arr topBtmArrow">&nbsp;</a>

		<div class="row">
			<div class="col-12 col-lg-3 pl-lg-5">
					<p class="fs-bold text-secondary pb-1">Indication</p>
					<p class='indication-text'>NOURIANZ<sup>&reg;</sup> (istradefylline) is an adenosine receptor antagonist indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing “off” episodes. </p>
			</div>
			<div id="isi" class="col-12 col-lg-9 pr-lg-5 pt-2 pt-lg-0">
					<p class="fs-bold text-secondary pb-1">Important Safety Information</p>
					<p><strong>Warnings and Precautions</strong></p>
					<p><strong>Dyskinesia:</strong> NOURIANZ in combination with levodopa may cause dyskinesia or exacerbate pre-existing dyskinesia. In clinical trials, 1% of patients treated with either NOURIANZ 20&nbsp;mg or 40&nbsp;mg discontinued treatment because of dyskinesia, compared to 0% for placebo.</p>
					<p><strong>Hallucinations / Psychotic Behavior:</strong> Because of the potential risk of exacerbating psychosis, patients with a major psychotic disorder should not be treated with NOURIANZ. Consider dosage reduction or discontinuation if a patient develops hallucinations or psychotic behaviors while taking NOURIANZ.</p>
					<p><strong>Impulse Control / Compulsive Behaviors:</strong> Patients treated with NOURIANZ and one or more medication(s) for the treatment of Parkinson’s disease (including levodopa) may experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge or compulsive eating, and/or other intense urges, and the inability to control these urges. In clinical trials, 1 patient treated with NOURIANZ 40&nbsp;mg was reported to have impulse control disorder, compared to no patient on NOURIANZ 20&nbsp;mg or placebo.</p>
					<p><strong>Drug Interactions</strong></p>
					<p>The maximum recommended dosage in patients taking strong CYP3A4 inhibitors is 20&nbsp;mg once daily. Avoid use of NOURIANZ with strong CYP3A4 inducers.</p>
					<p><strong>Specific Populations</strong></p>
					<p><strong>Pregnancy:</strong> Based on animal data, may cause fetal harm. </p>
					<p><strong>Hepatic impairment:</strong> The maximum recommended dosage of NOURIANZ in patients with moderate hepatic impairment is 20&nbsp;mg once daily. Avoid use in patients with severe hepatic impairment.</p>
					<p><strong>Adverse Reactions</strong></p>
					<p>The most common adverse reactions with an incidence ≥5% and occurring more frequently than with placebo were dyskinesia (15%, 17%, and 8%), dizziness (3%, 6%, and 4%), constipation (5%, 6%, and 3%), nausea (4%, 6%, and 5%), hallucination (2%, 6%, and 3%), and insomnia (1%, 6%, and 4%) for NOURIANZ 20&nbsp;mg, 40&nbsp;mg, and placebo, respectively.</p>
					<p>You are encouraged to report suspected adverse reactions to Kyowa Kirin, Inc. at <span class="no-wrap">1-844-768-3544</span> or FDA at <br class="d-none d-lg-block" /><span class="no-wrap">1-800-FDA-1088</span> or <a href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program" class="f-normal">www.fda.gov/medwatch</a>.</p>
					<p><strong>Please see full <a href="/assets/pdf/nourianz-full-prescribing-information.pdf" target="_blank">Prescribing Information</a> for NOURIANZ.</strong></p>
			</div>

			<div class="col-12 px-lg-5 pt-2 pb-4 py-lg-4">
					<div class="f-ref homeref">
						<p>
							<strong>References: 1.</strong> NOURIANZ. Prescribing Information. Kyowa Kirin, Inc; 2020. Accessed April 1, 2021. <a href="https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf" target="_blank">https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf</a>.
							<strong> 2.</strong>  Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson’s disease: review of recent trials. <i><em>Mov Disord</em>.</i> 2013;28(2):131-144.
						</p>

					</div>
					<div class="f-ref aboutref">
						<p>
							<strong>References: 1.</strong> Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials. <em>Mov Disord</em>. 2013;28(2):131-144. 
							<strong>2.</strong> Mori A. Mode of action of adenosine A<sub>2A</sub> receptor antagonists as symptomatic treatment for Parkinson’s disease. <em>Int Rev Neurobiol</em>. 2014;119:87-116. 
							<strong>3.</strong> Varani K, Vincenzi F, Tosi A, et al. A<sub>2A</sub> adenosine receptor overexpression and functionality, as well as TNF-α levels, correlate with motor symptoms in Parkinson’s disease. <em>FASEB J</em>. 2010;24(2):587-598. doi:10.1096/fj.09-141044.  
							<strong>4.</strong> Fuxe K, Marcellino D, Genedani S, Agnati L. Adenosine A<sub>2A</sub> receptors, dopamine D<sub>2</sub> receptors and their interactions in Parkinson's disease. <em>Mov Disord</em>. 2007;22(14):1990-2017. doi: 10.1002/mds.21440. 
							<strong>5.</strong> Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA. Role of adenosine A<sub>2A</sub> receptors in parkinsonian motor impairment and L-DOPA-induced motor complications. <em>Prog Neurobiol</em>. 2007;83(5):293-309. 
							<strong>6.</strong> Morelli M, Blandini F, Simola N, Hauser RA. A<sub>2A</sub> receptor antagonism and dyskinesia in Parkinson's disease. <em>Parkinsons Dis.</em> 2012;2012:489853. doi: 10.1155/2012/489853. 
							<strong>7.</strong> Mishina M, Ishiwata K. Adenosine receptor PET imaging in human brain. <em>Int Rev Neurobiol</em>. 2014;119:51-69. doi:10.1016/B978-0-12-801022-8.00002-7.
							<strong>8.</strong> The voice of the patient: Parkinson’s disease. Silver Spring, MD: US Food and Drug Administration; April 2016. https://www.fda.gov/media/124392/download. Accessed June 11, 2019. 
							<strong>9.</strong> Hickey P, Stacy M. Available and emerging treatments for Parkinson’s disease: a review. <em>Drug Des Devel Ther</em>. 2011;5:241-254.  
							<strong>10.</strong> Stocchi F, Antonini A, Barone P, et al. Early DEtection of wEaring off in Parkinson disease: the DEEP study. <em>Parkinsonism Relat Disord</em>. 2014;20(2):204-211.
						</p>
					</div>
					
					<div class="f-ref moaref">
						<p>
							<strong>References: 1.</strong> NOURIANZ. Prescribing Information. Kyowa Kirin, Inc; 2020. Accessed April 1, 2021. <a href="https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf">https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf</a>
							&nbsp<strong> 2.</strong> Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson’s disease: review of recent trials. <em>Mov Disord</em>. 2013;28(2):131-144. 
							<strong>3.</strong> Jenner P. Istradefylline, a novel adenosine A<sub>2A</sub> receptor antagonist, for the treatment of Parkinson’s disease. <em>Expert Opin Investig Drugs</em>. 2005;14(6):729-738. 
							<strong>4.</strong> Brichta L, Greengard P, Flajolet M. Advances in the pharmacological treatment of Parkinson’s disease: targeting neurotransmitter systems. <em>Trends Neurosci</em>. 2013;36(9):543-554.  
							<strong>5.</strong> Kaakkola S, Wurtman RJ. Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study. <em>Brain Res</em>. 1992;587(2):241-249.  
							<strong>6.</strong> Kong P, Zhang B, Lei P, et al. Neuroprotection of MAO-B inhibitor and dopamine agonist in Parkinson disease. <em>Int J Clin Exp Med</em>. 2015;8(1):431-439.  
							<strong>7.</strong> Ossola B, Schendzielorz N, Chen SH, et al. Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia. <em>Neuropharmacology</em>. 2011;61(4):574-582. 
							<strong>8.</strong> Rubí B, Maechler P. Minireview: new roles for peripheral dopamine on metabolic control and tumor growth: let’s seek the balance. <em>Endocrinology</em>. 2010;151(12):5570-5581. doi:10.1210/en.2010-0745. 
							<strong>9.</strong> Gerlach M, Double K, Arzberger T, Leblhuber F, Tatschner T, Riederer P. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum.  <em>J Neural Transm (Vienna)</em>. 2003;110(10):1119-1127.  
							<strong>10.</strong> Ishibashi K, Miura Y, Wagatsuma K, Toyohara J, Ishiwata K, Ishii K. Adenosine A<sub>2A</sub> receptor occupancy by long-term istradefylline administration in Parkinson’s disease. <em>Mov Disord</em>. 2021;36(1):268-269. doi:10.1002/mds.28378.
						</p>
					</div>

					<div class="f-ref effref">
						<p>
							<strong>References: 1.</strong> NOURIANZ. Prescribing Information. Kyowa Kirin, Inc; 2020. Accessed April 1, 2021. <a href="https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf" target="_blank" class="paragraphColor">https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf</a>
							&nbsp<strong> 2.</strong> Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson’s disease: review of recent trials. <em>Mov Disord</em>. 2013;28(2):131-144. 
							<strong>3.</strong> Data on file. Kyowa Kirin Pharmaceutical Development, Inc., Princeton, NJ.
						</p>
					</div>
					<div class="f-ref safetyref">
						<p>
							<strong>References: 1.</strong> NOURIANZ. Prescribing Information. Kyowa Kirin, Inc; 2020. Accessed April 1, 2021. <a href="https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf" target="_blank">https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf</a>
							&nbsp<strong>2.</strong> Data on file. Kyowa Kirin Pharmaceutical Development, Inc., Princeton, NJ.
						</p>
					</div>
					<div class="f-ref dosingref">
						<p><strong>Reference: 1.</strong> NOURIANZ. Prescribing Information. Kyowa Kirin, Inc; 2020. Accessed April 1, 2021. <a href="https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf" target="_blank">https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf</a>
					</div>
					<div class="f-ref accessref">
						<p><strong>Reference: 1.</strong> NOURIANZ. Prescribing Information. Kyowa Kirin, Inc; 2020. Accessed April 1, 2021. <a href="https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf" target="_blank">https://www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf</a>
					</div>
				
			</div>

		</div>

</div>	</div>

	<div class="footer">
		<div class="container mb-0">
			<div class="footer-container row">
				<div class="col-12 col-lg-7 pl-lg-5">
					
						<div class="links-section">
							<ul>
								<li class="footer-links">
									<a href="https://kkna.kyowakirin.com/wp-content/uploads/terms-and-conditions.pdf" class="text-gray" target="_blank">
										Terms and conditions
									</a>
								</li>
								<li class="footer-links">
									<a href="https://kkna.kyowakirin.com/wp-content/uploads/privacy-policy.pdf" class="text-gray" target="_blank">
										Privacy
									</a>
								</li>
								<li class="footer-links">
									<a href="https://www.kyowakirin.com/contact_us/index.html" class="text-gray" target="_blank">
										Contact
									</a>
								</li>
								
							</ul>
						</div>

						<div>
							<p class="cookieText">This website uses cookies to personalize content, save <br class="d-lg-none" />your preferences, and
								<br class="d-none d-lg-block" /> track its performance. 
								<br class="d-lg-none" /><br class="d-lg-none" />By continuing to use this website, you consent to <br class="d-lg-none" />the use
								<br class="d-none d-lg-block" /> of these cookies.</p>
						</div>
					
				</div>

				<div class="col-12 col-lg-5 pr-lg-5 pl-lg-0">
					
						<div class="logo-container my-5 mb-lg-4 pt-lg-0 mt-lg-0">
							<a href="https://kkna.kyowakirin.com/" target="_blank" class="mb-3 mb-lg-0 d-block">
								<img src="/assets/images/global/kyowa-kirin-logo.png" class="mx-auto d-block" alt="Kyowa Kirin logo" title="Kyowa Kirin logo">
							</a>
						</div>
						<span class="cr-txt">
							<p class="">NOURIANZ<sup style="font-size: 80%;" class="nreg sup2">&reg;</sup> is a registered trademark of Kyowa Kirin Co., Ltd.</p>
							<p class="pb-3 pb-lg-0">&ldquo;I Brake For Moments, Not For Parkinson&rsquo;s.&rdquo; is a trademark of Kyowa Kirin, Inc. </p>
							<p class="">©2021 Kyowa Kirin, Inc. All rights reserved. <br class="d-lg-none"> <span>PM-US-NOU-0044 December 2021</span></p>
						</span>
				
				</div>
				<div class="clearfix"></div>
			</div>
		</div>
	</div>
</footer>

<div class="modal fade in" id="hcpPopup" role="dialog">
	<div class="d-flex w-100 h-100 align-items-center">
		<div class="modal-dialog vertical-align-center">
			<!-- Modal content-->
			<div class="modal-content mw700">
				<div class="modal-body">
					<div class="interstitial interstialContainer hcpPopup">
						<h2 class="text-secondary text-center mb-0">Are you a US healthcare professional?</h2>
						<div class="d-flex flex-column align-items-md-center justify-content-between pt-5 px-0 px-lg-5">
							<a href="javascript:;" class="hcp-cta btn btn-primary text-white btn-close ml-md-5" data-dismiss="modal">YES</a>
							<a href="javascript:;" class="hcp-cta-none btn bg-gray text-white btn-close" data-dismiss="modal">NO</a>
						</div>
						<a href="javascript:;" class="int-close" data-dismiss="modal">
							<div></div>
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>

<!--external popup start-->
<div class="modal fade in" id="interstialPopup" role="dialog">
	<div class="d-flex w-100 h-100 align-items-center">
		<div class="modal-dialog vertical-align-center">
			<!-- Modal content-->
			<div class="modal-content mw700">
				<div class="modal-body">
					<div class="interstitial interstialContainer hcpPopup">
						<h2 class="text-secondary text-center">You are now leaving this site</h1>
						<p class="text-center pb-2">We do not review or control the content of external websites, and this <br class="d-none d-lg-block" />hyperlink does not constitute an endorsement of any other site’s content.</p>

							<div class="d-flex flex-column align-items-md-center justify-content-between pt-5 px-0 px-lg-5">
								<a href="javascript:;" class="btn btn-gray text-white btn-close" data-dismiss="modal">STAY</a>
								<a href="javascript:;" class="btn btn-primary text-white btn-continue proceedBut" target="_blank">PROCEED</a>
							</div>
						
						<a href="javascript:;" class="int-close" data-dismiss="modal">
							<div></div>
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>
<!--external popup end-->

<!-- Form Thank you Modal -->
<div class="modal fade in" id="mymodal" role="dialog">
	<div class="d-flex w-100 h-100 align-items-center">
		<div class="modal-dialog vertical-align-center">
			<!-- Modal content-->
			<div class="modal-content mw700">
				<div class="modal-body">
					<div class="interstitial interstitial-form	 interstialContainer hcpPopup">
						<h2 class="text-secondary text-center">Thank you for signing up</h2>
						<p class="text-center pb-2">You’re signed up to receive information from Kyowa Kirin. <br> Please check your inbox for a confirmation email.</p>
						<div class="d-flex flex-column align-items-md-center justify-content-center">
							<a href="javascript:;" class="hcp-cta btn btn-primary text-white btn-close" data-dismiss="modal">CLOSE</a>
						</div>
						<a href="javascript:;" class="int-close" data-dismiss="modal">
							<div></div>
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>
<script src="/assets/js/jquery.min.js"></script>
<script src="/assets/js/jquery-migrate-1.4.1.min.js"></script>
<script src="/assets/js/jquery.uniform.js"></script>
<script src="/assets/js/bootstrap.min.js"></script>
<script src="/assets/js/main.js"></script>

<script src="https://kkcstr.blob.core.windows.net/assets/amp/main.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/gsap/3.8.0/gsap.min.js" integrity="sha512-eP6ippJojIKXKO8EPLtsUMS+/sAGHGo1UN/38swqZa1ypfcD4I0V/ac5G3VzaHfDaklFmQLEs51lhkkVaqg60Q==" crossorigin="anonymous" referrerpolicy="no-referrer"></script>

</body>

</html>